PubMed Health⌕ Search

Biomedical subjects

Joseph M Lane

Publications and source records attributed to Joseph M Lane.

13 recordsLinked to original sources
PubMed2003

Orthopedic management of vertebral and long bone fractures in patients with osteoporosis.

Because of the evolving demographics of the world's population, fracture surgeons must become experts in the treatment of fractures in osteoporotic bone. Toward this end, fracture surgeons are learning to modify the classic techniques of internal fixation to adapt them to the elderly population. Screws should be placed into the best quality of bone available, which, in most cases, is an opposing cortex. Screw fixation can be augmented using acrylic cement. When using plate fixation, stable bone contact at the fracture site is the most important factor in reducing strain in the plate. Shortening of the affected bone is advisable to achieve this contact in comminuted fractures. Plates should not be used to bridge areas of comminution in osteoporotic bone. Plates should generally be as long as is compatible with the affected bone, with screws placed as close to and as far away from the fracture site as possible. When confronted with diaphyseal fractures or fractures with metaphyseal-diaphyseal comminution, locked intramedullary nails can be used. Angled blade plates are applicable to osteoporotic metaphyseal fractures but should be used as tension band plates, which require stable load-sharing contact opposite the plate. Antiglide plating and use of tension band wires are also effective strategies for osteoporotic fractures. Finally, to reduce the morbidity of bone graft harvest and to ensure adequate volumes of graft, the use of bone graft substitutes is particularly applicable in elderly patients. All patients with evidence of osteoporosis should be started on a medical regimen to combat further bone loss that includes calcium supplementation with a prescription for antiresorptive agents, including bisphosphonates, calcitonin, or hormone replacement therapy.

Bone Transplantation↗
PubMed2003

Hip fractures among the elderly: causes, consequences and control.

This review examines all pertinent literature sources published in the English language between 1966 to the present concerning hip fracture epidemiology, hip fracture injury mechanisms, and hip fracture management strategies. These data reveal hip fractures have several causes, but among these, the impact of falls and muscle weakness, along with low physical activity levels seems to be the most likely explanation for the rising incidence of hip fracture injuries. Related determinants of suboptimal nutrition, drugs that increase fall risk and lower the safety threshold and comorbid conditions of the neuromuscular system may also contribute to hip fracture disability. A number of interventions may help to prevent hip fracture injuries, including, interventions that optimize bone mass and quality, interventions that help prevent falls and falls dampening interventions. Rehabilitation outcomes may be improved by comprehensive interventions, prolonged follow-up strategies and ensuring that all aging adults enjoy optimal health.

Aged↗
PubMed2003

Medical management of osteoporosis.

Osteoporosis is characterized by low-energy fractures resulting from inadequate bone mass and compromised microarchicture. Bone mass is maximized by adequate nutrition and calcium intake, normal menstrual cycles, and appropriate exercises. Low bone density, as determined by dual-energy x-ray absorptiometry, and high bone turnover, as characterized by elevated bone collagen breakdown products, are the primary indicators of bone fragility. Prevention and treatment of osteoporosis should emphasize adequate calcium and vitamin D intake and exercise. In addition, estrogen supplementation and selective estrogen receptor modulators (estrogen antagonists) can enhance bone mass and decrease the risk of spinal fractures, oral and intravenous bisphosphonates can significantly decrease the incidence of both spinal and hip fractures, and antiosteoporotic agents can help rebuild healthy bone.

Aged↗
PubMed2002

Safety profile for the clinical use of bone morphogenetic proteins in the spine.

STUDY DESIGN: A review was conducted. OBJECTIVE: To determine the safety profiles of human recombinant bone morphogenetic protein-2 (rhBMP-2) and osteogenic protein-1 (OP-1) used clinically in spine applications. SUMMARY OF BACKGROUND DATA: Safety issues associated with the use of bone morphogenetic proteins in spine applications include the possibility of bony overgrowth, interaction with exposed dura, cancer risk, systemic toxicity, reproductive toxicity, immunogenicity, local toxicity, osteoclastic activation, and effects on distal organs. These issues have been given detailed examination in both human and animal studies, and safety data are available for both rhBMP-2 and OP-1. The safety data available for OP-1 are less detailed. METHODS: The study involved reviews of published reports and the safety data submitted to the Food and Drug Administration (rhBMP-2 and OP-1) and to the European Agency for the Evaluation of Medicinal Products (OP-1), as well as personal communication with the manufacturers of rhBMP-2 (Medtronic Sofamore Danek, Memphis, TN) and OP-1 (Stryker Biotech, Hopkinton, MA). RESULTS: Application of either rhBMP-2 or OP-1 to raw decorticated bony surfaces leads to new bone formation, which is desirable in the intertransverse or interbody regions. However, new bone formation also may occur if rhBMP-2 or OP-1 comes in contact with laminectomy sites or decompressed neuroforamina, and may lead to restenosis. Inadvertent placement of either rhBMP-2 or OP-1 in the spinal canal leads to formation of bone. Leakage of rhBMP-2 or OP-1 outside the fusion area may lead to adjacent-level fusion. Accurate placement of these factors and adequate retention by their carrier are highly important factors in minimizing these problems. Subdural bone formation occurs if OP-1 is implanted directly beneath the dura. Osteoclastic overstimulation does not appear to be a significant problem with rhBMP-2. However, bone resorption has been associated with OP-1 used in the setting of thoracolumbar fractures. Findings show that RhBMP-2 has an antiproliferative effect on many cancer cells, and no evidence exists that it is carcinogenic. It is unlikely that OP-1 has carcinogenic potential, although fewer data are available. Systemic and local toxicity, significant adverse effects, and harmful effects on distant organs have not been observed in either human or animal studies on rhBMP-2 and OP-1. The benign safety profile of rhBMP-2 may result from its rapid systemic clearance, which results in very little systemic exposure. Systemic exposure to OP-1 also is low. No reproductive toxicity has been observed with either rhBMP-2 or OP-1. However, there is no human safety data. Subclinical immune responses in human subjects to collagen carriers have been reported. Antibody responses to rhBMP-2 have been detected in less than 1% of spine patients. Low titer immune responses have been observed in 38% of patients treated with OP-1. There were no associated clinical adverse effects. CONCLUSIONS: Given the available data, both rhBMP-2 and OP-1 appear to be safe provided they are used appropriately, placed accurately, not allowed to come into contact with decompressed areas, and contained in the region of fusion. They must be used with caution in the presence of dural defects.

Animals↗
PubMed2002

Bone morphogenetic proteins: relevance in spine surgery.

Bone morphogenetic proteins (BMPs) are low molecular weight glycoproteins that play a vital role in the development and maturation of skeletal tissue. Bone morphogenetic protein-induced mesenchymal cell recruitment and differentiation leads to the formation of chondroblasts and osteoblasts leading to the formation of de novo bone. Overwhelming pre-clinical and clinical evidence has suggested a promising role for BMPs for anterior and posterolateral spinal fusion. Strength of this approach lies in the potential ability of these growth factors to reverse inhibitory conditions common in the clinical setting and enabling predictable fusion. However, several issues related to carriers, costs, and dosages still need to be consecutively addressed. Gene therapy techniques producing in vivo osteoinductive factors and utilizing minimally invasive approaches are attractive options being developed for the future.

Animals↗
PubMed2002

Nonmedical management of osteoporosis.

Nonmedical therapies are playing an increasing role in the management of osteoporosis and its complications. They serve as useful adjuncts to medical treatment. Several areas of nonmedical options for the management of osteoporosis include bracing, exercise, and vertebroplasty and kyphoplasty.

Braces↗
PubMed2002

Improvement in the undertreatment of osteoporosis following hip fracture.

BACKGROUND: Osteoporosis is a common disease characterized by decreased bone mass and increased fracture risk in postmenopausal women and the elderly. Hip fractures are among the most common consequences of osteoporosis and unfortunately usually occur late in the course of the disease. When a patient is admitted to the hospital with a fragility hip fracture, a unique opportunity for diagnosis and treatment presents itself. Fortunately, several medications have proven to be effective in lowering the risk of future fractures. The purposes of the present study were to test the hypothesis that most fragility hip fractures go untreated and to determine whether educational efforts to raise physician awareness have led to an improvement in osteoporosis treatment rates. METHODS: A retrospective cohort study was performed with use of the patient databases at two university medical centers and one university-affiliated community hospital. The charts of 300 randomly selected patients were sorted with use of ICD-9 (International Classification of Diseases, Ninth Revision) codes for femoral neck fractures. There were 100 patients from each center, with twenty-five patients from each year between 1997 and 2000. The admitting diagnosis, mechanism of injury, admission medications, procedures performed during hospitalization, and discharge medications were then extracted and analyzed. During this period, the National Osteoporosis Foundation established guiding principles for the treatment of fragility fractures. RESULTS: Of the seventy-five patients from all centers for each year from 1997 to 2000, 11%, 13%, 24%, and 29%, respectively, were discharged with a prescription for some medication targeting osteopenia, either supplemental calcium or an antiosteoporotic medication (estrogen, calcitonin, a bisphosphonate, or raloxifene). A trended chi-square analysis of this increase revealed a p value of <0.001, indicating that this improvement in treatment was unlikely due to chance alone. Fifty-eight (19.3%) of the 300 patients in the study received a prescription at the time of discharge. However, forty of these patients (13.3% of the overall group) received calcium and only eighteen (6.0% of the overall group) received a medication to actively prevent bone resorption and treat osteoporosis. In addition, no patient underwent a bone density scan while in the hospital. CONCLUSIONS: Elderly patients and postmenopausal women who are admitted to the hospital and diagnosed with a low-energy femoral neck fracture have been undertreated for osteoporosis. However, over the four years of the present study, there was a significant increase in the rate of treatment. It is hoped that treatment rates will continue to increase in the future with continued educational efforts.

Aged↗
PubMed2002

Resorbable posterolateral graft containment in a rabbit spinal fusion model.

OBJECT: The authors studied the effect of a resorbable graft containment device in a rabbit posterolateral lumbar spinal fusion model. METHODS: Twenty rabbits were divided into four groups: autologous bone graft (ABG), ABG with the MacroPore containment device (ABG + MP), demineralized bone matrix (DBM), and DBM with the containment device (DBM + MP). Fusion mass was assessed at 6 weeks with high-resolution radiography and volumetric computerized tomography. The graft containment device was associated with alteration of the fusion mass structure and significant enhancement of fusion mass volume (ABG versus ABG + MP, p = 0.027; DBM versus DBM + MP, p = 0.043). CONCLUSIONS: A bioabsorbable protective graft containment device successfully enhanced posterolateral spinal fusion mass volume.

Absorbable Implants↗
PubMed2002

Resorbable posterolateral graft containment in a rabbit spinal fusion model.

The effect of a resorbable graft containment device was evaluated in a rabbit posterolateral lumbar spinal fusion model. Twenty rabbits were divided into four groups: autogenous bone graft (ABG), ABG with the MacroPore containment device (MacroPore Biosurgery Inc, San Diego, Calif) (ABG+MP), demineralized bone matrix (DBM), and DBM with the containment device (DBM+MP). Fusion mass was assessed at 6 weeks with high resolution radiographs and volumetric computed tomography (CT). The graft containment device was associated with alteration of the fusion mass structure and significant enhancement of fusion mass volume (ABG versus ABG+MP, P=.027; DBM versus DBM+MP, P=.043). A bioabsorbable, protective graft containment device successfully enhanced posterolateral spinal fusion mass volume.

Absorbable Implants↗
PubMedDate not supplied

Bisphosphonates.

Explore the source record for details and available documents.

Bone Diseases, Metabolic↗